ArticleFrontiers in public health2025
Global, regional, and national burdens of rheumatoid arthritis among people aged 60 years and older from 1990 to 2021: a trend analysis for the Global Burden of Disease Study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Associations between oral microbiome diversity and rheumatoid arthritis in U.S. adults: NHANES 2009-2012.Acta odontologica Scandinavica · 2026Article
- The relationship between medication possession index and functional prognosis in patients with rheumatoid arthritis: a national longitudinal cohort study from CHARLS.International journal of surgery (London, England) · 2026Article
- Association between estimated cardiorespiratory fitness and arthritis in older adults: evidence from four large cohorts.Clinical rheumatology · 2026Article
- A UHPLC-Orbitrap-MS Metabolomics Strategy Reveals Glycerophospholipid Metabolic Remodeling Is Associated with the Anti-Arthritic Effect of Glycyrrhiza Protein-Paeoniflorin Nanoparticles via PI3K/AKT/NLRP3 Axis.Molecules (Basel, Switzerland) · 2026Article
- From data to action: leveraging Global Burden of Disease Studies for rheumatic and musculoskeletal diseases.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) poses a significant global health burden, especially among individuals aged 60 and older. This study analyzes RA burden trends using 2021 Global Burden of Disease (GBD) data. Methods: Utilizing the GBD 2021 data, we extracted detailed metric on RA incidence, prevalence, mortality, and disability-adjusted life years (DALYs) specifically for those aged 60 and above. Linear regression analysis was applied to calculate the overall average annual percentage change (AAPC) spanning from 1990 to 2021. Furthermore, Joinpoint regression was employed to identify the years with the most significant changes in global trends. A nuanced stratified analysis was also performed, examining global trends across age groups, genders, and sociodemographic indices (SDI). Results: From 1990 to 2021, both the age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR) of RA in people aged 60 and above worldwide has increased ASIR rose from 24.87 per 100,000 to 30.32 per 100,000 (95% uncertainty interval [UI] 19.83-42.38), while ASPR climbed from 635.51 per 100,000 to 726.91 per 100,000 (95% UI 634.05-834.80). Conversely, the age-standardized death rate (ASDR) and age-standardized DALYs rate declined, with ASDR decreasing from 4.18 per 100,000 to 3.20 per 100,000 (95% UI 2.58-3.72), and DALYs rate dropping from 150.83 per 100,000 to 143.20 per 100,000 (95% UI 113.39-178.43). Regionally, ASIR surged in North Africa and Middle East, Southeast Asia, and Andean Latin America, with ASPR peaking in Andean Latin America. Central Europe saw ASDR decline, while Central Asia's DALYs rate rose. Nationally, Vietnam's ASIR soared, and Ireland topped ASIR, ASPR, and DALYs rates. In 2021, for the global population aged 60 and above with RA: ASIR peaked at 65-69 years, ASPR peaked at 75-79 years; ASDR rose with age, and the age-standardized DALYs rate peaked at 85-89 years. Women bore a heavier RA burden. A non-linear SDI-DALYs relationship was noted, with Honduras and Mexico having high DALYs rates. Conclusion: From 1990 to 2021, the global ASIR and ASPR of RA increased among the older adult, while ASDR and age-standardized DALYs rate declined. Despite improvements, RA remains a public health priority, necessitating enhanced early diagnosis, treatment, and awareness, particularly among older adult women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.